A robust pipeline in pursuit of transformative therapies.

We are working hard to address significant unmet need in cancer and autoimmune disease, paving the way for future treatments.

Tabelecleucel (tab-cel®)

Tab-cel® is under investigation for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) and is in earlier stage development for other EBV-associated diseases.

LEARN MORE arrow_forward_ios
  • RR EBV+ PTLD following SOT or HCT
    Phase 3
    EU Approved
  • Multi-cohort: EBV+ cancers
    Phase 2

Next-generation allogeneic CAR T programs

Our focus is on applying natural T-cell biology and novel chimeric antigen receptor technologies to advance a new class of off-the-shelf CAR T-cell therapies in oncology and autoimmune disease.


ATA3219 is an allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, currently in clinical development, leveraging the EBV T-cell platform and features a next-generation 1XX co-stimulatory domain, memory phenotype, and unedited T-cell receptor.

LEARN MORE arrow_forward_ios


  • Non-Hodgkin’s Lymphoma (NHL)
    Phase 1


  • Lupus Nephritis (LN)
    Systemic Lupus Erythematosus (SLE) without lymphodepletion
    Phase 1


Off-the-shelf allogeneic CD19/CD20 CAR T program progressing toward an IND submission in H2 2025.

LEARN MORE arrow_forward_ios
  • B-cell malignancies
  • Autoimmune disease

Additional next-generation AlloCAR T programs

We’re tackling the limitations and challenges of current CAR T therapies by developing novel next-generation allogeneic CAR T approaches.

LEARN MORE arrow_forward_ios
  • Hematological malignancies and solid tumor AlloCAR T programs

Off-the-shelf, allogeneic approach for multiple sclerosis


ATA188 is an investigational, allogeneic T-cell immunotherapy targeting EBV-infected B cells and plasma cells that are believed to cause MS.

LEARN MORE arrow_forward_ios
  • Progressive multiple sclerosis (PMS)
    Phase 2

External Scientific Presentations

May, 2024

ATA3219: Allogeneic CD19 CAR EBV T Cells for the Treatment of B-Cell Driven Autoimmune Diseases


December, 2023

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T-cells for the Treatment of B-Cell Malignancies


February 2023

Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing


May 2020

Phase 1 Study of the Safety and Efficacy of ATA188, an Off-the-shelf, Allogeneic Epstein-Barr Virus-targeted T-cell Immunotherapy to Treat Progressive Forms of Multiple Sclerosis


April 2019

Functional Demonstration of CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells: An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform


These are investigational agents. Efficacy and safety have not been established.

See what makes our technology unique.